Literature DB >> 17675623

Successful treatment of mesenteric varices with balloon-occluded retrograde transvenous obliteration via an abdominal wall vein.

Satoshi Ono1, Toshiyuki Irie, Masashi Kuramochi, Toshiro Kamoshida, Shinji Hirai, Yuji Oka.   

Abstract

Balloon-occluded retrograde transvenous obliteration (BRTO) is an established therapy for gastric varices, but it has been used less frequently for mesenteric varices. This report describes the successful management of mesenteric varices with BRTO performed via an abdominal wall collateral vein detected on contrast medium-enhanced computed tomography.

Mesh：

Year:  2007        PMID： 17675623     DOI： 10.1016/j.jvir.2007.05.020

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN： 1051-0443            Impact factor:   3.464


  4 in total

1.  Percutaneous transhepatic sclerotherapy for bleeding ileal varices associated with portal hypertension and previous abdominal surgery.

Authors:  Toshihiro Iguchi; Kazuhisa Yabushita; Kohsaku Sakaguchi; Takeshi Hosoya; Daisaku Inoue; Hidefumi Mimura; Susumu Kanazawa
Journal:  Jpn J Radiol       Date:  2010-02-26       Impact factor: 2.374

2.  Variations of Balloon-occluded Retrograde Transvenous Obliteration (BRTO): Balloon-occluded Antegrade Transvenous Obliteration (BATO) and Alternative/Adjunctive Routes for BRTO.

Authors:  Wael E A Saad; Daniel Y Sze
Journal:  Semin Intervent Radiol       Date:  2011-09       Impact factor: 1.513

3.  Balloon-occluded retrograde transvenous obliteration of gastric varices: concept, basic techniques, and outcomes.

Authors:  Wael E A Saad
Journal:  Semin Intervent Radiol       Date:  2012-06       Impact factor: 1.513

4.  Successful treatment of mesenteric varices by retrograde transvenous obliteration by the delivery of N-butyl-2-cyanoacrylate via an abdominal wall vein.

Authors:  Osamu Ikeda; Yutaka Nakasone; Koichi Yokoyama; Seijiro Inoue; Hiroshi Takamori; Hideo Baba; Yasuyuki Yamashita
Journal:  Cardiovasc Intervent Radiol       Date:  2013-05-29       Impact factor: 2.740
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.